Harmony buys Epygenix for $35M upfront fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today reported preliminary, unaudited fourth quarter and full year 2023 net product revenue.
Zynerba Pharmaceuticals’ lead drug candidate is designed to bring the therapeutic effect of cannabinoids without also causing euphoric effects. The synthetic cannabinoid in a topical gel formulation includes none of the psychoactive compounds from the cannabis plant.